Founded Year

2016

Stage

Series A | Alive

Total Raised

$22.82M

Last Raised

$20M | 1 yr ago

About Multiply Labs

Pharmacube, dba Multiply Labs, was founded to provide individuals the freedom to customize their intake of supplements to optimize their day. Multiply Labs is leveraging robots and 3D printing to build made-to-order personal supplements, and people can also specify the duration of delivery for drugs like caffeine to take effect at the right time. In using patent-pending release technology developed at MIT and the University of Milan, Multiply Labs wants to change the way that people think about and take supplements.

Multiply Labs Headquarter Location

1760 Cesar Chavez Unit D

San Jose, California, 95124,

United States

615-218-2489

Multiply Labs's Product Videos

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Multiply Labs's Products & Differentiation

See Multiply Labs's products and how their products differentiate from alternatives and competitors

  • Robotic Cluster for Parallel Production of Batch-sized Capsule-based Products

    Fully autonomous, cloud-controlled robotic system for parallel production of small-batch, personalized capsule-based products. We have the ability to product multi-compartment drug products with several APIs at specified, personalized dosages.

    Differentiation

    We provide the only product on the market that can produce small batches of capsule drug products (down to 48 capsules per batch). This enables the selection of personalized dosages and personalized… 

  • Subscribe to see more

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

    Differentiation

    We're on a mission to enable every organization to make smarter decisions about tech. Whether it's finding a new game-changing vendor or understanding a new market, it's easier, faster and smarter with CB Insights. All made possible by the smartest, hardest-working team in tech. Subscribe to see more.

Research containing Multiply Labs

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Multiply Labs in 1 CB Insights research brief, most recently on Sep 10, 2019.

Expert Collections containing Multiply Labs

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Multiply Labs is included in 5 Expert Collections, including Vitamin & Supplement Startups.

V

Vitamin & Supplement Startups

649 items

R

Robotics

1,962 items

This collection includes startups developing autonomous ground robots, unmanned aerial vehicles, robotic arms, and underwater drones, among other robotic systems. This collection also includes companies developing operating systems and vision modules for robots.

F

Food & Beverage

2,859 items

W

Wellness Tech

1,312 items

We define wellness tech as companies developing technology to help consumers improve their physical, mental, and social well-being. Companies in this collection play across a wide range of categories, including food and beverage, fitness, personal care, and corporate wellness.

B

Beauty & Personal Care

858 items

These startups aim to provide health treatments, diagnosis tools, and products that do not require a prescription or connection with a health professional to enhance personal wellbeing. This includes supplements, women's health maintenance, OTC medicines, and more.

Multiply Labs Patents

Multiply Labs has filed 6 patents.

The 3 most popular patent topics include:

  • Fluid dynamics
  • Pharmaceutical industry
  • Sedimentology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/19/2021

12/14/2021

Biotechnology, Manufacturing, Production and manufacturing, Pharmaceutical industry, Life sciences industry

Grant

Application Date

4/19/2021

Grant Date

12/14/2021

Title

Related Topics

Biotechnology, Manufacturing, Production and manufacturing, Pharmaceutical industry, Life sciences industry

Status

Grant

Latest Multiply Labs News

Boy bands and psoriatic arthritis? NSYNC’s Lance Bass creates new dance for Amgen about early signs

May 12, 2022

Beth Snyder Bulik Senior Editor NSYNC boy band member Lance Bass didn’t realize his aches and pains weren’t just a byproduct of a busy lifestyle, new parenthood and of course, aging. Instead, it was psoriatic arthritis. Now Bass is partnering with Amgen and its anti-inflammatory biologic brand Otezla to help others recognize the signs of psoriatic arthritis. The singer and dancer, whose career began as one of the five boys of NSYNC with popular hit songs and coordinated dance move videos such as “Bye Bye Bye” and “It’s Gonna Be Me,” is translating those moves to a short TikTok-style “Double Take” dance. Keep reading Endpoints with a free subscription Unlock this story instantly and join 141,900+ biopharma pros reading Endpoints daily — and it's free. SIGN UP John Carroll Editor & Founder Roche has racked up its second straight Phase III fail for its TIGIT tiragolumab, flagging a flop on the progression-free survival co-primary endpoint for the drug combined with Tecentriq as a first-line treatment for PD-L1 high patients suffering from non-small cell lung cancer. The other co-primary endpoint in the SKYSCRAPER-01 study on overall survival hasn’t reached the readout phase yet. But this time around Roche execs are waiting to see if it just might hit positive after seeing numerical gains for both endpoints. Keep reading Endpoints with a free subscription Unlock this story instantly and join 141,900+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Josh Sullivan Associate Editor There’s a bottleneck in manufacturing right now, and perhaps the category that is the best representative of the issue is cell and gene therapy. Several companies are trying different things to address the issue, but Multiply Labs has enlisted some CDMO powerhouses on its path toward the automation of the process. Cytiva and the University of California-San Francisco were already members of the robotic cell therapy manufacturing consortium Multiply, founded in 2021. Last week, it was announced that Thermo Fisher Scientific and Charles River Laboratories have joined the team to help develop a cGMP-compliant system that can make gene-modified cell therapies at an individual scale. Read More May 12, 2022 02:20 PM EDT

Multiply Labs Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Multiply Labs Rank

  • When was Multiply Labs founded?

    Multiply Labs was founded in 2016.

  • Where is Multiply Labs's headquarters?

    Multiply Labs's headquarters is located at 1760 Cesar Chavez, San Jose.

  • What is Multiply Labs's latest funding round?

    Multiply Labs's latest funding round is Series A.

  • How much did Multiply Labs raise?

    Multiply Labs raised a total of $22.82M.

  • Who are the investors of Multiply Labs?

    Investors of Multiply Labs include Garage Capital, Fifty Years Fund, Lux Capital, Casdin Capital, Pathfinder and 10 more.

  • Who are Multiply Labs's competitors?

    Competitors of Multiply Labs include Cellino and 2 more.

  • What products does Multiply Labs offer?

    Multiply Labs's products include Robotic Cluster for Parallel Production of Batch-sized Capsule-based Products and 1 more.

You May Also Like

O
Ori Biotech

Ori Biotech develops a proprietary, flexible manufacturing platform that closes, automates, and standardizes manufacturing, allowing therapeutics developers to further develop and bring their products from pre-clinical process development to commercial scale manufacturing.

C
Cellares

Cellares is a cell therapy manufacturing technology startup in South San Francisco. Cellares is creating the future of cell therapy manufacturing and accelerating access to life-saving cell therapies. The company is developing a one-of-a-kind solution to overcome the limitations associated with manufacturing cell therapies to make them more affordable and widely available to patients in need. With Cellares' proprietary platform, The Cell Shuttle, biopharma companies, academic research centers and CDMOs will no longer have to compromise by either choosing a manufacturing platform that is semi-automated but lacks workflow flexibility, or one that provides customization but not the end-to-end automation needed to manufacture at scale.

Cellino Logo
Cellino

Cellino is developing an intracellular delivery technique for gene editing applications.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.